Vitals & Signals

Physicians are already building their own clinical tools — responsibly, with patient privacy designed in from day one. The question isn't whether they should. It's whether the EHRs, the hospitals, and a privacy law written in 1996 for a fax-first world will open up to meet them — or keep forcing innovation to happen in the shadows.

The ambient AI scribe industry sold itself on burnout relief — but the dirty secret hiding in plain sight is that better documentation means higher billing codes, and a peer-reviewed JAMA paper plus a $2.3B BCBSA study just handed payers the ammunition to declare war.

The FDA is quietly rewriting the fundamental contract of clinical AI regulation — moving from a pre-market permission slip to a post-market surveillance regime — and every founder, investor, and clinician in this industry needs to understand what that means before the framework lands.

Utah handed an AI the authority to prescribe medications, a security firm broke it in a single conversation, and the FDA has never cleared a single LLM-based medical device — this week, the gap between how fast healthcare is deploying AI and how slowly the regulatory system is catching up became impossible to ignore.